ClinicalTrials.gg
Active, not recruitingNCT05945823Updated Sep 1, 2026

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

A Phase 2 interventional study of Futibatinib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma and Esophageal Squamous Cell Cancer, sponsored by Taiho Oncology, Inc.. Active, not recruiting at 22 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 246 studies in Adenocarcinoma Of Esophagus with a site in United States — 53 open to participants now, 73 under way, 7 of them phase 3. Adenocarcinoma Of Esophagus · United States.

Enrollment
93rd of 203
53 · median 49
Started
2023
with 11 others
Phase 2
125 of 246
17 open now
Primary completion
2026-10
later than 12 of 72 live
Registered
203rd of 246
by date

Among the 246 studies in Adenocarcinoma Of Esophagus with a site in United States, this one is the 93rd largest by enrollment of the 203 interventional ones that give a count, is one of 12 that started in 2023, is one of 125 in phase 2, reaches primary completion later than 12 of the 72 other live ones, and was the 203rd registered.

Adenocarcinoma Of Esophagus

354 studies on the registry are indexed under Adenocarcinoma Of Esophagus; 81 are open to participants now.

Browse Adenocarcinoma Of Esophagus studies →

Open to participants now

53 of the 246 studies in Adenocarcinoma Of Esophagus with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 70 Adenocarcinoma Of Esophagus studies recruiting now, 60 (86%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Adenocarcinoma Of Esophagus with a site in United States, or all of them as a file.
02

Study summary

This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.

Read the detailed description

Patients with locally advanced, unresectable or metastatic esophageal cancer (EC) or pancreatic ductal adenocarcinoma (PDAC) will receive futibatinib in combination with pembrolizumab plus standard of care (SOC) chemotherapy. Patients with EC will receive Investigator choice of chemotherapy (FP or mFOLFOX6), patients with PDAC will receive mFOLFIRINOX. Subjects will receive futibatinib in combination with pembrolizumab plus standard of care (SOC) chemotherapy during induction phase of the study and will continue on futibatinib in combination with pembrolizumab in consolidation phase.

03

Conditions studied

  • Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer
  • Esophageal Adenocarcinoma
  • Esophageal Squamous Cell Cancer
  • Siewert Type 1 GEJ Cancer
  • Pancreatic Cancer

Keywords

  • Futibatinib
  • Advanced esophageal cancer
  • Esophageal cancer
  • TAS-120
  • Immunotherapy
  • Esophageal squamous cell cancer (ESCC)
  • GEJ cancer
  • pancreatic ductal adenocarcinoma
  • pancreatic cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is ≥18 years of age at the time of
  2. Cohort A: or cytologically confirmed, locally advanced, unresectable or adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the esophagogastric junction (EGJ).
  3. Cohort B: Histologically or cytologically confirmed, locally advanced, unresectable or metastatic pancreatic ductal adenocarcinoma.
  4. No prior systemic treatment for locally advanced, unresectable or metastatic disease
  5. as defined by (RECIST) guidelines.
  6. (ECOG) performance status 0 or 1
  7. Adequate organ function
  8. Able to take medications orally

Exclusion criteria

Exclusion Criteria

  1. Has locally advanced disease that is resectable or potentially curable with radiation therapy (as determined by local investigator).
  2. Has an adenocarcinoma histology and is eligible to receive approved targeted therapy (eg, positive patients).
  3. Has received prior treatment with an /PD-L1 or FGF/FGFR targeting drug, or any other agent directed to stimulatory or co-stimulatory T-cell receptor.
  4. Has known additional that is progressing or requires active treatment.
  5. History or current evidence of calcium and phosphate homeostasis disorder
  6. Current evidence of retinal disorder
  7. Pregnant or lactating female.
  8. Has known or severe reaction to any of the study drugs or their .
  9. Has a diagnosis of immunodeficiency.
  10. Has known (HIV) and/or history of or C infections, or known to be positive for Hepatitis B antigen (HBsAg)/ Hepatitis B virus (HBV) DNA or antibody or RNA.
  11. Has an active disease that has required systemic treatment in the past 2 years
  12. Has a history of (noninfectious) pneumonitis that required or has current pneumonitis.
  13. Has had an allogenic tissue/organ transplant.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Cohort A

    Patients with Esophageal cancer (Adenocarcinoma or Squamous cell cancer) will receive Futibatinib administered once daily on a continuous dosing regimen in combination with pembrolizumab plus investigator choice of SoC chemotherapy (FP or mFOLFOX6) for 6 cycles (induction phase) following by Futibatinib combination with pembrolizumab (consolidation phase).

    Drug: Futibatinib · Drug: Pembrolizumab · Drug: Cisplatin · Drug: 5-FU · Drug: Oxaliplatin · Drug: Leucovorin · Drug: Levoleucovorin

  • Experimental
    Cohort B

    Patients with PDAC will receive Futibatinib administered once daily on a continuous dosing regimen in combination with pembrolizumab plus mFOLFIRINOX for 6 cycles (induction phase) following by Futibatinib combination with pembrolizumab (consolidation phase) .

    Drug: Futibatinib · Drug: Pembrolizumab · Drug: 5-FU · Drug: Oxaliplatin · Drug: Leucovorin · Drug: Levoleucovorin · Drug: Irinotecan

Interventions

  • TAS-120 20 mg tablets, oral; once daily

    Also known as: TAS-120

  • 400 mg once every 6-week-cycle, via IV infusion.

    Also known as: MK-3475, KEYTRUDA®

  • 80 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy

    Also known as: PLATINOL®

  • Drug5-FU

    4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy. 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy. 2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy.

    Also known as: ADRUCIL®

  • 85 mg/m\^2 Q2W via IV infusion, as part of mFOLFIRINOX or mFOLFOX6 chemotherapy. 2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy.

    Also known as: ELOXATIN®

  • 400 mg/m\^2 Q2W as part of mFOLFIRINOX or mFOLFOX6 chemotherapy.

    Also known as: calcium folinate, folinic acid, WELLCOVORIN®

  • 200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.

    Also known as: calcium levofolinate, levofolinic acid, FUSILEV®

  • 150 mg/m\^2 Q2W as part of mFOLFIRINOX chemotherapy.

06

What researchers measure

Primary outcomes

  1. ORR by investigator assessment

    Defined as the proportion of patients experiencing a best overall response of partial response (PR) or complete response (CR) (per RECIST 1.1), based on investigator assessment

    Time frame: 12 months

Secondary outcomes

  1. Treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0

    Safety will be assessed based on reported AEs (including SAEs), graded by CTCAE V5.0., and dose modifications.

    Time frame: 12 months

  2. DoR per investigator assessment

    defined as time from the first documentation of response to the first documentation of objective tumor progression or death due to any cause, whichever occurs first

    Time frame: 12 months

  3. DCR per investigator assessment

    defined as percentage of patients who achieve complete response, partial response or stable disease per RECIST 1.1 by investigator assessment

    Time frame: 12 months

  4. PFS per investigator assessment

    defined as the time from date of enrollment to the date of disease progression based on Investigator assessment of radiographic images or death, whichever occurs first

    Time frame: 12 months

  5. 6-month PFS rate

    defined as percentage of patients without disease progression within 6 months of enrollment

    Time frame: 12 months

07

Study locations

22 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Oct 2026, 38 months after the start.

Of 60 phase 2 interventional studies under Adenocarcinoma Of Esophagus, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 80. This study's planned 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2023
First posted
Jul 14, 2023
StartActual
Jul 13, 2023
Primary completionEst.
Oct 1, 2026
CompletionEst.
Jan 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05945823
Responsible party
Sponsor
First posted
Jul 14, 2023
Start date
Jul 13, 2023
Primary completion
Oct 1, 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Sep 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Futibatinib

Start the discussion